摘要
目的分析乙型肝炎肝硬化和慢性乙型肝炎患者接受恩替卡韦治疗的临床效果。方法选取2012年4月—2014年7月我院的30例乙型肝炎肝硬化患者作为肝硬化组进行分析,同期选取30例慢性乙型肝炎患者作为乙肝组,对两组进行了96周的恩替卡韦治疗,对两组的治疗情况进行对比分析。结果肝硬化组患者治疗前后的白蛋白和总胆红素改善明显,差异有统计学意义(P<0.01)。治疗过程中没有出现严重不良反应病例,两组的血常规和肾功能复查正常,没有血液损害和肾功能损害情况出现。结论乙型肝炎硬化患者接受恩替卡韦治疗的效果比慢性乙型肝炎患者更佳,临床中患者的各项指标改善明显,没有严重不良反应。
Objective To analyze the clinical effects of entecavir for hepatitis B cirrhosis and chronic hepatitis B patients. Methods 30 cases of hepatitis B cirrhosis in our hospital from April 2012 to July 2014 were selected as the liver cirrhosis group. In the same period, 30 patients with chronic hepatitis B were selected as the hepatitis B group, and the two groups were treated with entecavir for 96 weeks. The treatment of the two groups was compared and analyzed. ResultsThe improvement of albumin and total bilirubin was significant before and after treatment in the patients with liver cirrhosis, and the difference was statistically significant（P〈0.01）. There were no cases of severe adverse reactions during the treatment, and the two groups of blood routine and renal function reexamination were normal. There was no blood damage and renal impairment. Conclusion The effect of entecavir treatment in hepatitis B sclerotic patients is better than that in patients with chronic hepatitis B, and there are no serious adverse reactions in clinical indicators.
作者
段秀贤
DUAN Xiuxian(Electrocardio Room, Daqing Second Hospital, Daqing Heilongjiang 163461, China)
出处
《中国继续医学教育》
2018年第2期121-123,共3页
China Continuing Medical Education
关键词
乙型肝炎
肝硬化
恩替卡韦
hepatitis B
liver cirrhosis
entecavir
